## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.1% in lower entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Caution: MRS_5 (-0.4%) diverging from MRS_20, watch for reversal. Outperforming sector by 5.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($50.72)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Accenture helps Bristol Myers Squibb to launch AI-based medical content hub Mosaic**
- Source: Times of India | 20251217T210857 | Bullish | Relevance: 100%
- Bristol Myers Squibb and Accenture have launched Mosaic, an AI-powered medical content hub in Mumbai, India. This hub utilizes generative AI to create patient-centric content and aims to enhance communication between the biopharmaceutical company and healthcare professionals. The initiative is part of Bristol Myers Squibb's $130 million investment in AI projects and leverages India's tech talent to accelerate commercialization efforts and improve healthcare content delivery globally.

**2. Is Bristol Myers (BMY) Undervalued After Its Recent Share Price Rebound?**
- Source: Simply Wall Street | 20251217T034657 | Neutral | Relevance: 100%
- Bristol-Myers Squibb (BMY) has seen a recent rebound in its share price, rising approximately 16% over the last month, despite a previous dip in revenue. While a "narrative fair value" suggests the stock is slightly overvalued at $54.23, Simply Wall St's DCF model indicates it might be significantly undervalued by about 54%, implying a potential intrinsic value of $117.66. This divergence highlights differing perspectives on the company's true value, with factors like patent cliffs and pricing reforms posing potential risks.

**3. Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies**
- Source: PR Newswire | 20251217T000558 | Bullish | Relevance: 100%
- Harbour BioMed has announced a multi-year global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. This partnership leverages Harbour BioMed's proprietary Harbour Mice® technology platform and could lead to payments totaling $90 million, plus potential development and commercial milestones of up to $1.035 billion, along with tiered royalties. The collaboration aims to accelerate programs and bring transformative therapies to patients worldwide.

**4. Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)**
- Source: ts2.tech | 20251216T194428 | Bullish | Relevance: 100%
- Bristol-Myers Squibb (BMY) is under scrutiny after a Bank of America upgrade, with investors weighing the ongoing patent cliff narrative against potential 2026 pipeline catalysts. BofA raised its price target to $61, citing anticipated "de-risking" events from 4-6 programs, while the company also announced its 17th consecutive annual dividend increase. The stock currently trades in the mid-$50s, amidst a "tug-of-war" between concerns over patent expirations and a potentially undervalued intrinsic worth based on discounted cash flow models.

**5. Bristol Myers Squibb opens a new AI-powered content hub, ‘Mosaic’, in Mumbai**
- Source: Pharmabiz.com | 20251216T120828 | Bullish | Relevance: 100%
- Bristol Myers Squibb, in partnership with Accenture, has launched 'Mosaic', an AI-powered content hub in Mumbai, India. This generative AI-enabled facility aims to revolutionize commercialization by creating patient-centric content and accelerating digital capabilities in real-time. The initiative is part of BMS's $130 million investment in AI to enhance marketing, improve patient experience, and strategically leverage India's digital expertise for global operations.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $108.6B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.9 |
| Current P/E | 8.2 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 6.1% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 (-0.4%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.3% shows strong absolute momentum above own 20MA. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.13% (CS: 88) | Strong |
| RSI_14 | 66.8 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.125x | Above |
| vs SMA200 | 1.093x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $53.34
- **Stop Loss:** $50.72 (4.9% risk)
- **Target:** $57.27 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 362
- **Position Value:** $19,309.08
- **Portfolio %:** 19.31%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*